摘要
目的探讨乳腺癌患者凝血酶激活的纤溶抑制物(TAFI)水平变化及临床意义。方法收集45例乳腺癌患者、30例乳腺良性病变患者及40例健康对照者,其中乳腺癌患者分为Ⅰ期17例,Ⅱ期15例及Ⅲ期13例。发色底物法测定血浆TAFI活性。同时检测D-二聚体及Fbg水平。结果与健康对照者和乳腺良性病变患者相比,乳腺癌患者血浆TAFI、D-二聚体及Fbg浓度显著上调(P<0.05),而良性病变组与健康对照组上述指标间无显著差异(P>0.05)。TAFI及Fbg浓度在不同分期乳腺癌患者中无显著差异(P>0.05),而D-二聚体水平则随着肿瘤进展不断上调。结论乳腺癌患者血浆TAFI水平显著升高,可能是乳腺癌患者凝血-纤溶功能紊乱的标志,但与乳腺癌患者分期间无显著相关性。
Objective To detect the changes of plasma thrombin-activated fibrinolysis inhibitor（TAFI） in breast cancer patients,and to investigate the correlation between different stages of cancer and the levels of TAFI. Methods Blood samples were collected from 45 breast cancer patients,30 patients with bengin breast disorders and 50 healthy controls. The levels of TAFI,D-D and fibrinogen（Fbg） were investigated. Then the relationship between these markers and tumor stages were analyzed. Results Compared with healthy control and bengin breast disorder patients,breast cancer patients had higher TAFI,D-D and Fbg（P〈0.05）,while no significant difference between healthy control and bengin breast disorder patients were observed. Moreover,there were no significant differences between TAFI,D-D and tumor stages. However,D-D was increasing with cancer progressing. Conclusion Breast cancer patients have significantly higher TAFI levels,while there was no significant correlation with tumor stages.
作者
熊超
曾灵芝
廖立潇
XIONG Chao ZENG Lingzhi LIAO Lixiao(Department of oncology,the First People＇s Hospital of Jiujiang Nanchang University Affiliated Jiujiang Hospital, Jiujiang 332000, China)
出处
《江西医药》
CAS
2017年第7期620-622,共3页
Jiangxi Medical Journal
